GlobeNewswire·Nov 12, 2026, 10:00 AM ET

DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years

DBVT

DBV Technologies presented new data from the Phase 3 VITESSE study of the VIASKIN® Peanut Patch at the 2026 ACAAI Annual Scientific Meeting in Phoenix, Arizona.
The study randomized 654 children aged 4 to 7 years to receive either the VIASKIN® Peanut Patch (250 µg peanut protein) or placebo for 12 months.
Treatment with the patch resulted in a statistically significant reduction in maximum symptom severity during double-blind, placebo-controlled food challenges at month 12 compared to placebo.
46.6% of children in the treatment arm met responder criteria at month 12 versus 14.8% in the placebo arm, representing a 31.8% difference in response rates.
Immunologic changes consistent with allergen immunotherapy included increased peanut-specific IgG4, decreased peanut-specific IgE, decreased Ara h 2-specific IgE, and reduced skin-prick-test wheal diameter.
Mean treatment compliance was high at 96.1%, with most participants reporting patches were easy & not painful to remove.
The study protocol required no restrictions on daily activities or concomitant medications, allowing participants to continue bathing, sports, & swimming.
Severe reactions occurred in 8.4% of treated participants versus 12.5% in the placebo group during food challenges at month 12.
When reactions were assessed at or below baseline eliciting doses, 52.7% of treated participants had no symptoms versus 19.2% in the placebo group.
DBV Technologies remains a late-stage biopharmaceutical company headquartered in Châtillon, France, with the VIASKIN® Peanut Patch currently under regulatory review & not yet authorized for sale.

Company: DBV Technologies S.A.
Keywords: Paris Stock Exchange:DBV, DBV Technologies S.A.